Summary
NanoCarrier Co Ltd (NanoCarrier) is a biopharmaceutical products provider that research, develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s research and development pipeline comprise NC-6004, NC-4016, NC-63000/K-912 and NK105. It provides siRNA micelle, protein micelle, DACH-platin micelle, paclitaxel micelle, pH-sensitive micelle, sensor linked micelle and docetaxel micelle. NanoCarrier’s micellar nanoparticle technology is also applicable in developing cosmetics and healthcare products. The company’s products find application in treating breast cancer, head and neck cancer, solid cancer and non-small cell lung cancer. NanoCarrier is headquartered in Kashiwa, Japan.
NanoCarrier Co Ltd (4571) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NanoCarrier Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
NanoCarrier Enters into Research Agreement with University of Utah 11
NanoCarrier will Enter into Research Agreement with TPG Biologics 12
NanoCarrier Enters Into R&D Agreement With Shin-Etsu Chemical For Cancer Treatment 13
NanoCarrier and LFB Biotechnologies Enter into Research Agreement 14
NanoCarrier Extends Research Agreement With Kyoto University 15
NanoCarrier Enters Into Co-Development Agreement With Eisai 16
NanoCarrier Enters Into Research Agreement With Kyoto University 17
Licensing Agreements 18
TODAI TLO Enters into Licensing Agreement with NanoCarrier 18
NanoCarrier Extends Licensing Agreement With Orient Europharma For NC-6004 Nanoplatin 19
NanoCarrier Enters Into Licensing Agreement With NOF For Nucleotide Delivery Polymer 20
Equity Offering 21
NanoCarrier Agrees to Invest in Tocagen 21
NanoCarrier Completes Private Placement Of Shares For US$4.3 Million 22
NanoCarrier Completes Public Offering Of Shares For US$89 Million 23
NanoCarrier Completes Private Placement Of Shares Upon Exercise Of Warrants For US$20 Million 24
NanoCarrier Completes Private Placement Of Shares For US$8.6 Million 25
Debt Offering 26
NanoCarrier Completes Private Placement Of First Series Bonds For US$10.8 Million 26
NanoCarrier Completes Private Placement Of Second Series Bonds For US$11 Million 27
NanoCarrier Co Ltd - Key Competitors 28
NanoCarrier Co Ltd - Key Employees 29
NanoCarrier Co Ltd - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 10, 2016: NanoCarrier: Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2017 31
Product News 33
10/21/2016: Acceleration of Development of NC-6300 33
01/05/2017: Notice on the Initiation of the Phase I/II Clinical Study on NC-6300 (Epirubicin Micelle) for Patients with Rare Cancers in the U.S. 34
Clinical Trials 35
Jul 06, 2016: NanoCarriers position on the announcement from Nippon Kayaku about NK105 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NanoCarrier Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
NanoCarrier Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
NanoCarrier Enters into Research Agreement with University of Utah 11
NanoCarrier will Enter into Research Agreement with TPG Biologics 12
NanoCarrier Enters Into R&D Agreement With Shin-Etsu Chemical For Cancer Treatment 13
NanoCarrier and LFB Biotechnologies Enter into Research Agreement 14
NanoCarrier Extends Research Agreement With Kyoto University 15
NanoCarrier Enters Into Co-Development Agreement With Eisai 16
NanoCarrier Enters Into Research Agreement With Kyoto University 17
TODAI TLO Enters into Licensing Agreement with NanoCarrier 18
NanoCarrier Extends Licensing Agreement With Orient Europharma For NC-6004 Nanoplatin 19
NanoCarrier Enters Into Licensing Agreement With NOF For Nucleotide Delivery Polymer 20
NanoCarrier Agrees to Invest in Tocagen 21
NanoCarrier Completes Private Placement Of Shares For US$4.3 Million 22
NanoCarrier Completes Public Offering Of Shares For US$89 Million 23
NanoCarrier Completes Private Placement Of Shares Upon Exercise Of Warrants For US$20 Million 24
NanoCarrier Completes Private Placement Of Shares For US$8.6 Million 25
NanoCarrier Completes Private Placement Of First Series Bonds For US$10.8 Million 26
NanoCarrier Completes Private Placement Of Second Series Bonds For US$11 Million 27
NanoCarrier Co Ltd, Key Competitors 28
NanoCarrier Co Ltd, Key Employees 29
NanoCarrier Co Ltd, Other Locations 30
List of Figures
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NanoCarrier Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
